

## APC anti-mouse CD45 Antibody

<b>Catalog# / Size</b>	103111 / 25 µg 103112 / 100 µg
<b>Clone</b>	30-F11
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T200, Ly-5, LCA
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.  Additional reported applications (for relevant formats) include: immunoprecipitation <sup>3</sup> , complement-dependent cytotoxicity <sup>1,5</sup> , immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections) <sup>4,6</sup> , Western blotting <sup>7</sup> , and spatial biology (IBEX) <sup>10,11</sup> . The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

### Application References

(PubMed link indicates BioLegend citation)

1. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (FC, CMCD) [PubMed](#)
2. Haynes NM, *et al.* 2007. *J. Immunol.* 179:5099. (FC)
3. Ledbetter JA, *et al.* 1979. *Immunol. Rev.* 47:63. (IP)
4. Simon DI, *et al.* 2000. *J. Clin. Invest.* 105:293. (IHC)
5. Seaman WE. 1983. *J. Immunol.* 130:1713. (CMCD)
6. Cornet A, *et al.* 2001. *P. Natl. Acad. Sci. USA* 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. *J. Biol. Chem.* 273:30680. (WB) [PubMed](#)
8. Liu F, *et al.* 2012. *Blood.* 119:3295. [PubMed](#)
9. Pelletier AN, *et al.* 2012. *J. Immunol.* 188:5561. [PubMed](#)

10. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
11. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Gavin KM, *et al.* 2018. *Front Endocrinol (Lausanne).* 9:276. [PubMed](#)
2. Wang L, *et al.* 2018. *Bone Res.* 6:22. [PubMed](#)
3. Cha JH *et al.* 2018. *Molecular cell.* 71(4):606-620. [PubMed](#)
4. Haimon Z *et al.* 2018. *Nature immunology.* 19(6):636-644. [PubMed](#)
5. Ying W, *et al.* 2019. *Cell Metab.* 29:457. [PubMed](#)
6. Strickley JD, *et al.* 2019. *Nature.* 575:519. [PubMed](#)
7. Jiang Z, *et al.* 2021. *J Clin Invest.* 131: . [PubMed](#)
8. Garo LP, *et al.* 2021. *Nat Commun.* 12:2419. [PubMed](#)
9. Shah D, *et al.* 2021. *Oncoimmunology.* 10:1939601. [PubMed](#)
10. Kuo PC, *et al.* 2021. *Brain Commun.* 3:fcab187. [PubMed](#)
11. Nigam S, *et al.* 2020. *Mol Imaging Biol.* 22:685. [PubMed](#)
12. Yang D, *et al.* 2022. *Cell.* 185:1905. [PubMed](#)
13. Tan L, *et al.* 2022. *Aging Dis.* 13:1562. [PubMed](#)
14. Bouchareychas L, *et al.* 2021. *iScience.* 24(8):102847. [PubMed](#)
15. Almada AE, *et al.* 2021. *Cell Reports.* 34(4):108656. [PubMed](#)
16. Kim JS, *et al.* 2020. *Immunity.* 54(1):176-190.e7. [PubMed](#)
17. Garcia-Fabiani MB, *et al.* 2020. *Methods Enzymol.* 632:369. [PubMed](#)
18. Jaiswal AK, *et al.* 2020. *Immunobiology.* 225:151956. [PubMed](#)
19. Cayre S, *et al.* 2020. *Development.* 147:00:00. [PubMed](#)
20. Díaz NM, *et al.* 2020. *Invest Ophthalmol Vis Sci.* 61:37:00. [PubMed](#)
21. Mourao L, *et al.* 2019. *Sci Rep.* 0.991666667. [PubMed](#)
22. Oetjen LK *et al.* 2017. *Cell.* 171(1):217-228. [PubMed](#)
23. Testini C, *et al.* 2019. *EMBO Rep.* 20:e47845. [PubMed](#)
24. Gao Q, *et al.* 2019. *J Exp Med.* 216:688. [PubMed](#)
25. Shavit Stein E, *et al.* 2018. *Neural Plast.* 2018:7692182. [PubMed](#)
26. Ahmed M, *et al.* 2016. *Development.* 143: 1663 - 1673. [PubMed](#)
27. Yu K, *et al.* 2021. *Cell Reports.* 35(12):109273. [PubMed](#)
28. Lim JT, *et al.* 2020. *Mol Cancer Ther.* 1809:19. [PubMed](#)
29. Karlen SJ, *et al.* 2018. *J Neuroinflammation.* 15:344. [PubMed](#)
30. Du Q, *et al.* 2019. *Front Microbiol.* 10:2050. [PubMed](#)
31. Kang I, *et al.* 2012. *Blood.* 119:3295. [PubMed](#)
32. Rosa FF, *et al.* 2020. *Bio Protoc.* 10:e3619. [PubMed](#)
33. Wang Y, *et al.* 2021. *J Bone Oncol.* 30:100386. [PubMed](#)
34. Lu L, *et al.* 2022. *Sci Rep.* 12:931. [PubMed](#)
35. Parhiz H, *et al.* 2022. *J Control Release.* 344:50. [PubMed](#)
36. Yanagida K, *et al.* 2020. *Dev Cell.* 779:52. [PubMed](#)
37. Hirano KI, *et al.* 2021. *eLife.* 0.416666666666667. [PubMed](#)
38. Larouche JA, *et al.* 2021. *eLife.* 0.416666666666667. [PubMed](#)
39. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
40. Barberio AE, *et al.* 2020. *ACS Nano.* 14:11238. [PubMed](#)
41. Chiche A, *et al.* 2016. *Oncogene.* 10.1038/onc.2016.396. [PubMed](#)
42. Eastman A, *et al.* 2016. *J Immunol.* 194: 5999-6010. [PubMed](#)
43. Engelbrecht E, *et al.* 2020. *eLife.* 9:e52690. [PubMed](#)
44. Hays C, *et al.* 2020. *eLife.* 8:e48772. [PubMed](#)
45. Lechner AJ *et al.* 2017. *Cell stem cell.* 21(1):120-134. [PubMed](#)
46. Chen J, *et al.* 2022. *Nat Commun.* 13:6759. [PubMed](#)
47. Wang S, *et al.* 2022. *Front Immunol.* 13:869061. [PubMed](#)
48. Zhang Y, *et al.* 2022. *Cancers (Basel).* 14: [PubMed](#)
49. Barwe SP, *et al.* 2022. *J Clin Med.* 11: [PubMed](#)
50. Tilstam PV, *et al.* 2021. *J Clin Invest.* 131: [PubMed](#)
51. Yu X, *et al.* 2021. *Nature.* 594:560. [PubMed](#)
52. Sato S, *et al.* 2021. *Int J Mol Sci.* 22: [PubMed](#)
53. Oliva Chávez AS, *et al.* 2021. *Nat Commun.* 12:3696. [PubMed](#)
54. Strunz M, *et al.* 2020. *Nat Commun.* 2.929861111. [PubMed](#)
55. Shemer A, *et al.* 2020. *Immunity.* 53(5):1033-1049.e7. [PubMed](#)
56. Schiller M, *et al.* 2021. *Immunity.* 54(5):1022-1036.e8. [PubMed](#)
57. Wosczyzna MN, *et al.* 2021. *Cell Stem Cell.* 28(7):1323-1334.e8. [PubMed](#)
58. Okuniewska M, *et al.* 2021. *Cell Reports.* 36(2):109368. [PubMed](#)
59. Zhao B, *et al.* 2021. *Cell Reports.* 36(3):109401. [PubMed](#)
60. Motoyama S, *et al.* 2020. *Cells.* :9. [PubMed](#)
61. Jin X, *et al.* 2019. *Mol Cell.* 73:22:00. [PubMed](#)
62. Duarte N, *et al.* 2018. *HepatoL Commun.* 0.833333333. [PubMed](#)
63. Park JA, *et al.* 2021. *J HematoL Oncol.* 14:142. [PubMed](#)
64. Romagnoli M, *et al.* 2020. *Development.* 147: [PubMed](#)
65. Li Q, *et al.* 2021. *Brain Behav Immun.* 94:437. [PubMed](#)
66. Wang X, *et al.* 2022. *Nat Aging.* 2:155. [PubMed](#)
67. Wang T, *et al.* 2020. *Blood Sci.* 2:79. [PubMed](#)
68. Lv H, *et al.* 2020. *Cell Metabolism.* 33(1):110-127.e5. [PubMed](#)
69. Amouyal C, *et al.* 2020. *EBioMedicine.* 58:102895. [PubMed](#)
70. Liu L, *et al.* 2015. *Neurol Neuroimmunol Neuroinflamm.* 2: 174. [PubMed](#)
71. Hyatt L, *et al.* 2014. *PLoS One.* 9:109072. [PubMed](#)
72. Pelletier A, *et al.* 2012. *J Immunol.* 188:5561. [PubMed](#)
73. Herting CJ, *et al.* 2019. *Brain.* 142:3834. [PubMed](#)
74. Romagnoli M, *et al.* 2019. *Stem Cell Reports.* 1.077083333. [PubMed](#)
75. Ning X, *et al.* 2019. *Mol Cell.* 74:19. [PubMed](#)

76. De S, *et al.* 2018. *Development*. 145. [PubMed](#)
77. Xiao X, *et al.* 2019. *Cell Discov*. 5:2. [PubMed](#)
78. Mauduit O, *et al.* 2022. *Front Immunol*. 13:1011125. [PubMed](#)
79. Chen Z, *et al.* 2022. *Theranostics*. 12:6242. [PubMed](#)
80. Xu X, *et al.* 2021. *J Nanobiotechnology*. 19:376. [PubMed](#)
81. Bourn JR, *et al.* 2021. *Cancer Lett*. 503:75. [PubMed](#)
82. Khateb M, *et al.* 2022. *Cell Rep*. 40:111219. [PubMed](#)
83. Xu Q, *et al.* 2022. *Proc Natl Acad Sci U S A*. 119:. [PubMed](#)
84. Liu K, *et al.* 2022. *Theranostics*. 12:639. [PubMed](#)
85. Sato Y, *et al.* 2021. *J Clin Invest*. Online ahead of print. [PubMed](#)
86. Lafkas D, *et al.* 2013. *J Cell Biol*. 203:47. [PubMed](#)
87. Ma S, *et al.* 2021. *Cell Reports*. 34(6):108726. [PubMed](#)
88. Ankawa R, *et al.* 2021. *Developmental Cell*. . [PubMed](#)
89. An J, *et al.* 2017. *Sci Rep*. 10.1038/s41598-017-13629-0. [PubMed](#)
90. Wosczyzna MN *et al.* 2019. *Cell Rep*. 27(7):2029-2035 . [PubMed](#)
91. Maston LD, *et al.* 2017. *Am J Physiol Lung Cell Mol Physiol*. 312:L609. [PubMed](#)
92. Bresson L, *et al.* 2018. *Development*. 145. [PubMed](#)
93. Charmsaz S, *et al.* 2017. *Leukemia*. 31:1779. [PubMed](#)
94. Sambasivan R, *et al.* 2011. *Development*. 138:3647. [PubMed](#)
95. Hu EY, *et al.* 2021. *Blood Adv*. 5:3152. [PubMed](#)
96. Palathingal Bava E, *et al.* 2022. *JCI Insight*. 7:. [PubMed](#)
97. Frier J, *et al.* 2021. *Immunity*. 54(5):1002-1021.e10. [PubMed](#)
98. Alshetaiwi H, *et al.* 2020. *Sci Immunol*. 5:00. [PubMed](#)
99. Kotfis K, *et al.* 2020. *British Journal of Pharmacology*. 49(1):66-72. [PubMed](#)
100. Xiao P, *et al.* 2019. *J Exp Med*. 216:337. [PubMed](#)
101. Varol D *et al.* 2017. *Immunity*. 46(6):1030-1044 . [PubMed](#)
102. Chen X *et al.* 2017. *Cell stem cell*. 21(6):747-760 . [PubMed](#)
103. Zheng B, *et al.* 2018. *J Hematol Oncol*. 11:16. [PubMed](#)
104. Pal B, *et al.* 2017. *Nat Commun*. 10.1038/s41467-017-01560-x. [PubMed](#)
105. Fischer A, *et al.* 2022. *Nat Immunol*. 23:518. [PubMed](#)
106. Hu J, *et al.* 2022. *Cell Mol Neurobiol*. . [PubMed](#)
107. Chen L, *et al.* 2021. *Cell Death Differ*. 28:1880. [PubMed](#)
108. Shcherbina A, *et al.* 2020. *Cell Rep*. 32:107964. [PubMed](#)
109. Wu J, *et al.* 2020. *Immunity*. 53:115. [PubMed](#)
110. Xie Z, *et al.* 2020. *Light Sci Appl*. 0.486805556. [PubMed](#)
111. Yuan Z, *et al.* 2018. *Emerg Microbes Infect*. 7:59. [PubMed](#)
112. Hou M, *et al.* 2020. *Stem Cell Res Ther*. 11:55. [PubMed](#)
113. Morimoto A, *et al.* 2021. *Nat Commun*. 12:2136. [PubMed](#)
114. Hanasoge Somasundara AV, *et al.* 2021. *Cell Rep*. 37:110099. [PubMed](#)
115. Thinarad R, *et al.* 2022. *Pharmaceutics*. 14:. [PubMed](#)
116. Yang H, *et al.* 2022. *Nutrients*. 14:. [PubMed](#)
117. Hu J, *et al.* 2022. *J Neuroinflammation*. 19:71. [PubMed](#)
118. Pezoldt J, *et al.* 2022. *Nat Commun*. 13:7227. [PubMed](#)
119. Jia Q, *et al.* 2021. *Theranostics*. 4699:11. [PubMed](#)
120. Paiva-Oliveira E, *et al.* 2017. *Histochem Cell Biol*. 10.1007/s00418-017-1556-6. [PubMed](#)
121. Dudek KA, *et al.* 2020. *Proc Natl Acad Sci U S A*. 117:3326. [PubMed](#)
122. Bradley KC, *et al.* 2019. *Cell Rep*. 28:245. [PubMed](#)
123. Crooks SD, *et al.* 2022. *Immunohorizons*. 6:705. [PubMed](#)
124. Yang J, *et al.* 2022. *Microbiome*. 10:149. [PubMed](#)
125. Harnett MM, *et al.* 2022. *Front Immunol*. 13:953053. [PubMed](#)
126. Koren E, *et al.* 2022. *Nat Commun*. 13:4628. [PubMed](#)
127. Bauer T, *et al.* 2021. *Life (Basel)*. 11:. [PubMed](#)
128. Li P, *et al.* 2022. *EMBO Mol Med*. 14:e14511. [PubMed](#)
129. Zuo S, *et al.* 2021. *J Immunother Cancer*. 9:. [PubMed](#)
130. Myerson JW, *et al.* 2021. *Nat Nanotechnol*. Online ahead of print. [PubMed](#)
131. Wang C, *et al.* 2011. *Hepatology*. 55:108. [PubMed](#)
132. Sim S, *et al.* 2016. *PLoS One*. 11: 0152485. [PubMed](#)
133. Mangum L, *et al.* 2016. *Toxicol Sci*. 150: 169 - 177. [PubMed](#)
134. Mizuno T, *et al.* 2017. *Sci Rep*. 7:42714. [PubMed](#)
135. Nosh S, *et al.* 2020. *Int J Mol Sci*. 21:00. [PubMed](#)
136. Engler AE, *et al.* 2020. *Cell Reports*. 33(13):108553. [PubMed](#)
137. Kaur A, *et al.* 2019. *Cancer Discov*. 9:64. [PubMed](#)
138. Liu S, *et al.* 2020. *Cell Host & Microbe*. 26(6):779-794.e8.. [PubMed](#)
139. Zhou G, *et al.* 2019. *FASEB J*. 33:11396. [PubMed](#)
140. Shannon JP, *et al.* 2021. *STAR Protoc*. 2:100790. [PubMed](#)
141. Yang Y, *et al.* 2022. *Elife*. 11:. [PubMed](#)
142. Dey S, *et al.* 2020. *J Immunother Cancer*. 8:. [PubMed](#)
143. Zhang Q, *et al.* 2022. *Nat Commun*. 13:2406. [PubMed](#)
144. Scur M, *et al.* 2022. *Nat Commun*. 13:7272. [PubMed](#)
145. Xi W, *et al.* 2021. *Stem Cell Res Ther*. 167:12. [PubMed](#)
146. Shannon JP, *et al.* 2021. *Immunity*. 54(2):276-290.e5. [PubMed](#)
147. Dawson CA, *et al.* 2021. *Nature Protocols*. 16(4):1907-1935. [PubMed](#)
148. Seki T, *et al.* 2015. *J Biochem*. 158: 485 - 495. [PubMed](#)
149. Yamada KJ, *et al.* 2020. *PLoS Pathog*. 16:e1008354. [PubMed](#)
150. Tu WL, *et al.* 2018. *Am J Pathol*. 188:2688. [PubMed](#)
151. Chiche A, *et al.* 2019. *Breast Cancer Res*. 21:13. [PubMed](#)
152. Feng J, *et al.* 2017. *Nat Commun*. 10.1038/s41467-017-01056-8. [PubMed](#)
153. Limbad C, *et al.* 2022. *iScience*. 25:103848. [PubMed](#)
154. Chiang HY, *et al.* 2022. *Nat Commun*. 13:874. [PubMed](#)
155. Aguilera M, *et al.* 2021. *Int J Mol Sci*. 22:. [PubMed](#)

156. Garcia-Bonilla L, *et al.* 2014. J Immunol. 193:2531. [PubMed](#)
157. Ding X, *et al.* 2015. J Immunol. 194:4251. [PubMed](#)
158. Wang L, *et al.* 2015. Cancer Immunol Res. 3: 1030-1041. [PubMed](#)
159. Mueller A, *et al.* 2016. Nature. 540:276-279. [PubMed](#)
160. Perry JL, *et al.* 2020. ACS Nano. 5.583333333. [PubMed](#)
161. Wei Z, *et al.* 2021. Nat Commun. 0.805555556. [PubMed](#)
162. Penkert RR, *et al.* 2020. Obesity (Silver Spring). 1631:28. [PubMed](#)
163. Mori A, *et al.* 2021. Cells. :10. [PubMed](#)
164. Echevarría-Vargas IM, *et al.* 2018. EMBO Mol Med. 10:e8446. [PubMed](#)
165. Shi R, *et al.* 2019. J Cancer. 10:367. [PubMed](#)
166. Subramanian K, *et al.* 2019. Nat Microbiol. 4:62. [PubMed](#)
167. Usmani SM *et al.* 2019. Cell host & microbe. 25(1):73-86. [PubMed](#)
168. Zaslona Z, *et al.* 2017. Am J Physiol Lung Cell Mol Physiol. 312:L855. [PubMed](#)
169. Nowlan B, *et al.* 2019. Haematologica. 105:71. [PubMed](#)
170. Liu D, *et al.* 2020. Front Pharmacol. 11:204. [PubMed](#)
171. Dion-Albert L, *et al.* 2022. Nat Commun. 13:164. [PubMed](#)
172. Long JT, *et al.* 2022. Elife. 11:. [PubMed](#)
173. Zhang Z, *et al.* 2021. Exp Dermatol. 30:102. [PubMed](#)
174. Han Y, *et al.* 2022. Int J Biol Sci. 18:5653. [PubMed](#)
175. Yang Y, *et al.* 2021. Cell Reports. 34(10):108822. [PubMed](#)
176. Taya M, *et al.* 2020. Endocr Relat Cancer. 27:261. [PubMed](#)
177. Cai B, *et al.* 2020. Cell Metabolism. 31(2):406-421.e7.. [PubMed](#)
178. Lu Y, *et al.* 2020. Immunity. 52:782. [PubMed](#)
179. Toyama K, *et al.* 2018. Arterioscler Thromb Vasc Biol. 38:1392. [PubMed](#)
180. Qiao S, *et al.* 2019. J Neuroinflammation. 16:4. [PubMed](#)
181. Takaku S, *et al.* 2022. Evid Based Complement Alternat Med. 2022:6122955. [PubMed](#)
182. Murdock BJ, *et al.* 2021. JCI Insight. 6:. [PubMed](#)
183. Elias S, *et al.* 2015. PLoS Biol. 13:1002142. [PubMed](#)
184. Deng P, *et al.* 2021. Cell Stem Cell. 28(6):1057-1073.e7. [PubMed](#)
185. Carmody C *et al.* 2019. Endocrinology. 160(5):1205-1222. [PubMed](#)
186. Fu NY, *et al.* 2018. Dev Cell. 47:629. [PubMed](#)
187. Yousef H, *et al.* 2019. Nat Med. 25:988. [PubMed](#)
188. Yeo SK, *et al.* 2020. eLife. 9:e58810.. [PubMed](#)
189. Zhang J, *et al.* 2022. Biomater Res. 26:44. [PubMed](#)
190. Hoover AR, *et al.* 2022. Clin Transl Med. 12:e937. [PubMed](#)
191. Zhang Y, *et al.* 2020. Cancer Res. 80:3345. [PubMed](#)
192. Bagati A, *et al.* 2020. Cancer Cell. 39(1):54-67.e9. [PubMed](#)
193. Nasser H, *et al.* 2020. Cell Death Discov. 0.29375. [PubMed](#)
194. Sroor HM, *et al.* 2019. Sci Rep. 9:20217. [PubMed](#)
195. Chen PY, *et al.* 2019. Nat Metab. 0.675. [PubMed](#)
196. Cao Y, *et al.* 2019. Nat Commun. 10:1280. [PubMed](#)
197. Liu L *et al.* 2018. Cell stem cell. 23(4):544-556. [PubMed](#)
198. Zheng Y, *et al.* 2022. J Immunol. 208:501. [PubMed](#)
199. Zhang T, *et al.* 2020. JCI Insight. 5:00. [PubMed](#)
200. Porrello A, *et al.* 2018. Nat Commun. 9:1988. [PubMed](#)
201. Cai T, *et al.* 2022. Nat Commun. 13:2228. [PubMed](#)
202. Kim KS, *et al.* 2022. JCI Insight. 7:. [PubMed](#)
203. Saber M, *et al.* 2020. Eur J Neurosci. 52:2791. [PubMed](#)
204. Vaas M, *et al.* 2016. J Cereb Blood Flow Metab. 10.1177/0271678X16676825. [PubMed](#)
205. Wong J, *et al.* 2016. Sci Signal. 9: ra103. [PubMed](#)
206. Yuan Z, *et al.* 2016. J Virol. 90: 7728 - 7739. [PubMed](#)
207. Garcia-Bonilla L, *et al.* 2015. J Neurosci. 35: 14783 - 14793. [PubMed](#)
208. Jiang Y, *et al.* 2015. MBio. 6: e01426-15. [PubMed](#)
209. Roberts L, *et al.* 2014. Infect Immun. 82:2504. [PubMed](#)
210. Ortiz A, *et al.* 2019. Cancer Cell. 35:33:00. [PubMed](#)
211. Ouadah Y, *et al.* 2019. Cell. 179:403. [PubMed](#)
212. Piotrowski AF, *et al.* 2018. Oncoimmunology. 7:e1445951. [PubMed](#)
213. Sarshad AA, *et al.* 2018. Mol Cell. 71:1040. [PubMed](#)
214. Gopalakrishnapillai A, *et al.* 2021. Cancers (Basel). 13:. [PubMed](#)
215. Liu G, *et al.* 2022. Theranostics. 12:2248. [PubMed](#)
216. Arora S, *et al.* 2021. Med (N Y). 2:938. [PubMed](#)
217. Li H, *et al.* 2022. iScience. 25:104481. [PubMed](#)
218. Cayre S, *et al.* 2020. Development. . [PubMed](#)
219. Endo-Umeda K, *et al.* 2021. Sci Rep. 11:22595. [PubMed](#)
220. Pal B, *et al.* 2021. Breast Cancer Res. 23:69. [PubMed](#)
221. Maller O, *et al.* 2020. Nat Mater. 20:548. [PubMed](#)
222. Jaeger N, *et al.* 2020. Cell Rep. 33:108331. [PubMed](#)
223. Koh BI, *et al.* 2020. Nat Commun. 3.143055556. [PubMed](#)
224. Ren D, *et al.* 2020. Am J Cancer Res. 2851:10. [PubMed](#)
225. Su M, *et al.* 2018. Immunol Cell Biol. 9:2448. [PubMed](#)
226. Wunderlich CM, *et al.* 2018. Nat Commun. 9:1646. [PubMed](#)
227. Peltzer N, *et al.* 2018. Nature. 557:112. [PubMed](#)
228. Qu Y, *et al.* 2020. Cell Reports. 32(1):107873. [PubMed](#)
229. Hu Y, *et al.* 2021. J Nanobiotechnology. 19:416. [PubMed](#)
230. Kastenschmidt JM, *et al.* 2021. Cell Rep. 35:108997. [PubMed](#)
231. Dai B, *et al.* 2021. Cell Reports Medicine. 2(8):100381. [PubMed](#)
232. Bravo JI, *et al.* 2021. STAR Protocols. 2(2):100406. [PubMed](#)
233. Chng S, *et al.* 2016. Sci Rep. 6: 23820. [PubMed](#)
234. Kabir AU, *et al.* 2018. JCI Insight. 3. [PubMed](#)
235. Quijano-Rubio A, *et al.* 2022. Nat Biotechnol. Online ahead of print. [PubMed](#)

236. Scheyltjens I, *et al.* 2022. *Nat Protoc.* 17:2354. [PubMed](#)  
 237. Liu C, *et al.* 2022. *Nat Commun.* 13:1989. [PubMed](#)  
 238. Saber M, *et al.* 2021. *J Neurotrauma.* 38:2862. [PubMed](#)  
 239. Wang Y, *et al.* 2022. *Nat Cell Biol.* 24:230. [PubMed](#)  
 240. Okubo A, *et al.* 2021. *Int J Mol Sci.* 23:.. [PubMed](#)  
 241. Deets KA, *et al.* 2021. *Elife.* 10:.. [PubMed](#)  
 242. Murray CW, *et al.* 2022. *Nat Commun.* 13:1090. [PubMed](#)  
 243. Song X, *et al.* 2022. *Transl Oncol.* 15:101306. [PubMed](#)  
 244. Zhong J, *et al.* 2021. *Commun Biol.* 4:865. [PubMed](#)  
 245. Xie Z, *et al.* 2020. *Light Sci Appl.* 9:161. [PubMed](#)

**RRID** AB\_312976 (BioLegend Cat. No. 103111)  
 AB\_312977 (BioLegend Cat. No. 103112)

## Antigen Details

---

<b>Structure</b>	Protein tyrosine phosphatase (PTP) family, 180-240 kD
<b>Distribution</b>	All hematopoietic cells except mature erythrocytes and platelets
<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
<b>Cell Type</b>	B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li> <li>2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.</li> <li>3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.</li> <li>4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.</li> </ol>
<b>Gene ID</b>	<a href="#">19264</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats


---

APC anti-mouse CD45, Biotin anti-mouse CD45, FITC anti-mouse CD45, PE anti-mouse CD45, PE/Cyanine5 anti-mouse CD45, Purified anti-mouse CD45, PE/Cyanine7 anti-mouse CD45, APC/Cyanine7 anti-mouse CD45, Alexa Fluor® 488 anti-mouse CD45, Alexa Fluor® 647 anti-mouse CD45, Pacific Blue™ anti-mouse CD45, Alexa Fluor® 700 anti-mouse CD45, PerCP/Cyanine5.5 anti-mouse CD45, PerCP anti-mouse CD45, Alexa Fluor® 594 anti-mouse CD45, Brilliant Violet 421™ anti-mouse CD45, Brilliant Violet 570™ anti-mouse CD45, Brilliant Violet 510™ anti-mouse CD45, Brilliant Violet 605™ anti-mouse CD45, Purified anti-mouse CD45 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45, Brilliant Violet 711™ anti-mouse CD45, Brilliant Violet 785™ anti-mouse CD45, Brilliant Violet 650™ anti-mouse CD45, APC/Fire™ 750 anti-mouse CD45, Brilliant Violet 750™ anti-mouse CD45, TotalSeq™-A0096 anti-mouse CD45, TotalSeq™-B0096 anti-mouse CD45, Ultra-LEAF™ Purified anti-mouse CD45, Spark Blue™ 550 anti-mouse CD45, Spark NIR™ 685 anti-mouse CD45, TotalSeq™-C0096 anti-mouse CD45, Spark YG™ 570 anti-mouse CD45, PE/Fire™ 640 anti-mouse CD45, APC/Fire™ 810 anti-mouse CD45, PE/Fire™ 700 anti-mouse CD45, Spark Violet™ 538 anti-mouse CD45, Spark YG™ 593 anti-mouse CD45, Spark Blue™ 574 anti-mouse CD45 Antibody

## Product Data

---

C57BL/6 mouse splenocytes stained  
with 30-F11 APC



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587